Search | Clinical Trials Finder

Conditions: Coronary Artery Disease
Interventions: Rosuvastatin; Drug
Lead sponsor: General University Hospital, Prague; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Maywood, Illinois • Iowa City, Iowa

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, etoposide, carboplatin, paclitaxel, thoracic radiotherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Hollywood, Florida + 18 more

Conditions: Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions: PY314, Combination Therapy: PY314 + Pembrolizumab; Drug
Lead sponsor: Ikena Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more

Conditions: Develop and Test Robotically Assisted Imaging System for the Front of the Eye
Interventions: Robotically Aligned Eye Imaging System; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions: eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA®), Placebo; Biological · Drug · Other
Lead sponsor: Immutep S.A.S.; Industry
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Louisville, Kentucky • Albuquerque, New Mexico • Austin, Texas

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: soy isoflavones, cisplatin, etoposide, pemetrexed disodium, radiation therapy; Dietary Supplement · Drug · Radiation
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 5
States / cities: Bay City, Michigan • Detroit, Michigan • Lapeer, Michigan + 2 more

Conditions: Pancreatitis, Chronic
Interventions: Mobile Mindfulness Therapy; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Kidney Transplantation
Interventions: Kidney biopsy; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more

Conditions: Diabetes Complications, Fatty Liver
Interventions: exenatide; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions: tesamorelin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • Boston, Massachusetts

Conditions: Neoplasms, Malignant, Breast Neoplasm, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasm, Head and Neck Neoplasms
Interventions: Carlo Erba Ink Injection, EPR Oximetry Measurement; Device · Other
Lead sponsor: Philip Schaner; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Muscle-Invasive Bladder Carcinoma, Tumor
Interventions: Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC); Drug
Lead sponsor: Leslie Ballas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 19 more

Conditions: Neoplasms
Interventions: Niraparib, Pembrolizumab, TSR-042 (Dostarlimab); Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more

Conditions: Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
Interventions: Panobinostat (LBH589), Sorafenib; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Wilson Disease
Interventions: Bis-Choline Tetrathiomolybdate; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Sacramento, California • Ann Arbor, Michigan • Dallas, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 5 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2029
U.S. locations: 5
States / cities: Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more

Conditions: Advanced Solid Tumors
Interventions: VVD-130037, Docetaxel, Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Vividion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 8
States / cities: Jacksonville, Florida • Sarasota, Florida • Tampa, Florida + 5 more

Conditions: NSCLC, Locally Advanced
Interventions: Cemiplimab, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC); Drug · Radiation
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pancreatic Cancer
Interventions: 16S rRNA gene sequencing assay; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years to 74 Years
Enrollment: 732 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Advanced
Interventions: Palbociclib 125mg; Drug
Lead sponsor: Razelle Kurzrock, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Eczema, Atopic Dermatitis
Interventions: Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy; Drug · Device
Lead sponsor: OptiSkin Medical; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Infliximab, Vedolizumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: Athens, Georgia • Lexington, Kentucky • Baltimore, Maryland + 6 more

Search by objective public record fields.

The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

A Study of PY314 in Subjects With Advanced Solid Tumors

Robotic OCT for ER Anterior Eye Exams

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis

Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

Tesamorelin Effects on Liver Fat and Histology in HIV

EPR Tumor Oximetry With CE India Ink

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Oral Microbiome and Pancreatic Cancer

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)